Solvonis Therapeutics plc is a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system disorders.
Headquartered in London and listed on the Main Market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and proprietary discovery-stage compounds across addiction and psychiatry.
